Document Detail


The use and limitations of unfractionated heparin.
MedLine Citation:
PMID:  20215909     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite the development of newer anticoagulants, unfractionated heparin remains an indispensible agent in the treatment of thrombotic disorders. Heparin exerts its major effect via antithrombin, converting antithrombin to a more efficient inhibitor of circulating thrombin (factor IIa), factor Xa, factor IXa, factor XIIa, and kallikrein. However, due to the multiple anticoagulant mechanisms of heparin, differential molecular weight-based clearance, issues of heparin resistance, and patient-specific characteristics (age, weight, gender, and tobacco), attaining therapeutic anticoagulation is complicated. As a result, a minority of patients in major clinical trials achieve an activated partial thromboplastin time within the target window in an appropriate time-frame despite the use of weight-based titration nomograms. The resultant under- or over-therapeutic anticoagulation is associated with increased risks of ischemic and bleeding complications, suggesting the importance of maintaining heparin anticoagulation within a relatively narrow therapeutic range. In this review we discuss the mechanisms of heparin action, clinical ramifications of incorrect dosing in major trials, and attempts to improve the achievement of therapeutic anticoagulation.
Authors:
Amar Krishnaswamy; A Michael Lincoff; Christopher P Cannon
Related Documents :
1735999 - Surgery for effort thrombosis of the subclavian vein.
7825099 - Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically treated patients.
352099 - A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis.
6229899 - Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery.
10595789 - Occurrence of anti-prothrombin and anti-beta2-glycoprotein i antibodies in patients wit...
12449719 - Low molecular weight heparin for venous thromboembolism prophylaxis in urologic oncolog...
20094959 - Descending nerve-sparing radical prostatectomy--results and consequences.
8333269 - Visual outcome after vitrectomy for diabetic retinopathy. a five-year follow-up.
19410989 - Comparative clinical outcomes of submuscular and subcutaneous transposition of the ulna...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Critical pathways in cardiology     Volume:  9     ISSN:  1535-2811     ISO Abbreviation:  Crit Pathw Cardiol     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-10     Completed Date:  2010-06-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101165286     Medline TA:  Crit Pathw Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  35-40     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / administration & dosage,  pharmacology*,  therapeutic use
Clinical Trials as Topic
Heparin / administration & dosage,  pharmacology*,  therapeutic use
Humans
Partial Thromboplastin Time
Thrombosis / drug therapy*
Chemical
Reg. No./Substance:
0/Anticoagulants; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Implementation of the guidelines for the management of patients with chest pain through a critical p...
Next Document:  The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosi...